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ABSTRACT
Introduction: Cognitive impairment in
multiple sclerosis (MS) is common even in the
early stages of the disease. Our objective was to
improve early detection of cognitive
impairment in MS.
Methods: Seventy-five patients with relapsing
remitting (RR) MS and 20 controls were
enrolled. Two RRMS groups were defined
according to their results at the Paced
Auditory Serial Addition Test (PASAT). Patients
with a z score below two standard deviations
were considered impaired. We quantified T2
and T1 lesion volumes, and cerebral white and
grey matter volumes on a conventional brain
magnetic resonance imaging (MRI) scan. Global
brain atrophy was evaluated using the third
ventricle (V3) width (in mm). An average brain
model was built based on controls and
compared with the patient’s MRI to quantify
regional volumetric changes.
Results: Sixteen (21.3%) patients with RRMS
had low PASAT performance. They had a higher
Expanded Disability Status Scale (EDSS) score
(P = 0.019). T2 and T1 lesion volumes, and grey
and white matter volumes were the same in
both groups. An enlargement of the V3 width
was observed in the low performer group
(P = 0.044) and V3 width was correlated with
the PASAT score (r = -0.271; P = 0.021). A
composite score, named HV3, was obtained by
adding the EDSS and V3 width (in mm) and
correlated with the PASAT (r = -0.325;
P = 0.006). A cutoff HV3 score of over 5.5
identified patients with low PASAT
performance, with a positive predictive value
of 92.5% and an accuracy of 70.1%. Focal
atrophy was detected in the supplementary
motor area, the cingulate gyrus, the right
thalamus, and the inferior parietal lobules of
patients with lower PASAT performance.
Conclusion: Specific brain morphological
changes, including an enlargement of the V3
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width, are associated with low PASAT
performance in patients with RRMS. The HV3
score is an additional and complementary tool,
accessible in clinical practice, to suspect easily
cognitive impairment in patients with RRMS
and to better identify patients requiring a
complete cognitive assessment.
Keywords: Brain atrophy; Brain MRI; Cognitive
impairment; Multiple sclerosis; V3 width
INTRODUCTION
Cognitive disorders are common in patients
with multiple sclerosis (MS) and occur in all MS
subtypes with a prevalence of between 40% and
70% [1]. They are not only most frequent in
progressive forms but are also present at the
early stage of the disease [2, 3]. However, their
pathophysiology is poorly understood. The
cognitive domains most frequently altered
include attention, speed of information
processing, and working memory [4]. The path
to diagnose cognitive disorders is often
complicated and requires the use of a battery
of tests, including at least 1 h of cognitive
assessment [5, 6]. Moreover, these batteries
can only be implemented by experienced
neuropsychologists and are not easy to use in
daily neurological practice.
Many magnetic resonance imaging (MRI)
parameters are known to be correlated with
cognitive impairment in MS, especially global
brain atrophy (in particular the width of the
third ventricle [V3]) or the basal ganglia volume
[7, 8]. The importance of the involvement of
the cortical grey matter volume was more
recently demonstrated [9]. Specific brain areas
were more atrophied in cognitively impaired
patients with relapsing–remitting (RR) MS,
especially the thalami, insula, the prefrontal
cortex, and regions in the temporo-occipital
lobes [10, 11]. In modern connectivity-based
approaches, researchers in diffusion-tensor
imaging have demonstrated that white matter
thalamocortical connections, which constitute
the executive system of working memory, were
structurally altered in patients with MS [12].
More recently, it has been shown that
functional connectivity changes in the
thalamocortical network occurred in patients
with MS and correlated with cognitive
performance [13]. Contradictory data
concerned the link between cognitive
impairment and T1 and T2 lesion loads [14, 15].
This study was designed to establish and
report correlations between neuropsychological
and conventional MRI data. The aim was to
improve early detection of cognitive
impairment in MS with a simple test based on
clinical examination and brain MRI, directly
usable during a physician consultation.
METHODS
Compliance with Ethics Guidelines
The study was approved by the Nice Ethics
Committee. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients and controls for
being included in the study.
Subjects
We prospectively enrolled patients with RRMS
followed at the tertiary MS center in Nice,
France. Patients with a history of psychiatric
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disorders, major depression, or substance abuse
were excluded. Demographic data were
recorded, including disease duration, first
symptoms, and disease-modifying treatment.
The level of education and laterality were
noted. Disability assessment was based on
validated scales: Multiple Sclerosis Functional
Composite (MSFC), Expanded Disability Status
Scale (EDSS), and Multiple Sclerosis Severity
Scale (MSSS). Fatigue was assessed with the
validated French fatigue scale ‘‘Echelle de
Mesure de l’Impact de la Fatigue sur la SEP’’
(EMIF-SEP) [16].
A group of 20 control patients with no
history of neurological or psychiatric diseases
was also recruited. Each control patient was
matched in age, gender, laterality, and level of
education with a subgroup of patients with
MS.
Cognitive Assessment
All patients and controls performed the Paced
Auditory Serial Addition Test (PASAT) 3, which
was used as a screening test for cognitive
assessment [17]. It is a complex test of
executive function, working memory,
information processing speed, and divided
attention. Results were expressed as z scores to
normalize data by age, gender, and level of
education by comparison with a standard
population [18]. Low performance at this test
was defined as a z score less than two standard
deviations (SD) below the normalized PASAT
mean.
Brain MRI
All subjects completed a 1.5 Tesla MRI
according to the same protocol. T1-weighted
(T1w), T2-weighted spin echo, fluid-attenuated
inversion recovery (FLAIR), and T1 with
gadolinium sequences were systematically
performed.
SepINRIA software was used to quantify the
T2, T1, and gadolinium lesion loads, and grey
and white matter volumes [19]. Global atrophy
was indirectly measured on FLAIR sequences by
the third ventricle (V3) width, lateral ventricles
width, bicaudate ratio, and brain diameter, as
described in previous studies [7, 20, 21].
Measures were done manually by two
independent evaluators using OsiriX software
(Geneva, Switzerland) [22]. Each measure was
controlled twice by each evaluator and the
average value was conserved for statistical
analysis.
To quantify the change in regional volumes,
we created a template T1w-MR image by
averaging the 3D T1w-MR images from the
control group using the methodology presented
by Guimond [23]. This average anatomical
model of the human brain was then fused
with a digital brain atlas from the Montreal
Neurological Institute to identify each structure
together and with the International
Consortium for Brain Mapping (ICBM) atlas to
identify white matter tracts. Each patient’s MRI
was then compared with the average brain
model using Jacobian integration to quantify
regional volumetric changes. Analysis was
conducted using anatomical or functional
segmentation (Broadmann areas). As some
studies have demonstrated the structures
involved in the execution of the PASAT, we
specifically focused on the variation in volume
of these structures [24].
Statistical Analysis
Statistical analysis was performed using the
XLSTAT software (Addinsoft, France). For the
univariate analysis, the Chi square test was used
for categorical data. The Student’s t test was
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used for quantitative data. When the
distribution was not normal (analysis of
variance), the Mann–Whitney test was used.
When samples were too small the Fisher’s exact
test was used for comparison. The level of
significance was set at P\0.05. Threshold V3
and composite score threshold EDSS ? V3 width
(HV3 score, chapter results), predictive of low
PASAT performance, was calculated using the
receiver operating characteristic (ROC) curve
and analyzed at the Youden plot. The Pearson’s
correlation test was performed for continuous
variables to determine the presence of a
correlation between cognitive performance
and clinical and imaging data.
RESULTS
Demographic and Cognitive Data
Seventy-five patients with RRMS were enrolled,
57 female and 18 male. All patients were
treated with beta interferon. The patients
characteristics were mean (±SD) age 36.1 ±
9.2 years, mean (±SD) level of education
12.8 ± 2.4 years, mean (±SD) disease duration
6.9 ± 7.3 years, median (range) EDSS 1.5
(0–5.5), mean (±SD) standardized PASAT
41.65 ± 12.3, and mean EMIF-SEP 30.5 ± 21.2.
Low performance on the PASAT was detected
in 16/75 (21.3%) of patients with MS. The mean
(±SD) PASAT score in the MS group with a low
PASAT performance was 22.17 ± 6.27 against
47.48 ± 7.92 in the MS group with normal
PASAT performance.
The demographic, clinical, and imaging data
of both groups were compared to identify
specific parameters associated with a low
PASAT performance. There was no difference
in age, disease duration, treatment duration or
type of treatment, gender, or level of education.
EDSS was significantly higher in the group with
low PASAT performance, with a median (range)
of 2.0 (1–5.5) against 1.5 (0–5) in the group with
normal performance (P = 0.019). There was no
difference in the analysis of the MSSS. There was
no difference between the groups for the
annualized relapse rate. Patients with MS who
demonstrated low performance in the PASAT
showed no increase in fatigue. In particular,
there was no difference in the cognitive
dimension assessed with the EMIF-SEP. All
results are presented in Tables 1 and 2.
Brain MRI Analysis
MS Patients vs. Controls
Patients with MS showed a significant
enlargement of the V3 width compared with
controls (P = 0.0001). Similarly, brain width
was significantly reduced in the MS group
(P = 0.0003). There was no difference between
the two groups regarding the bicaudate
ratio and the width of the lateral ventricles
(Tables 3, 4).
Impaired vs. Unimpaired Patients with MS
There was no significant difference in the T1,
T2, and gadolinium lesion loads, and white
matter volume and grey matter volume between
the both MS groups.
The width of the V3 was significantly
increased in the group with low PASAT
performance (P = 0.044). There was no
difference in the width of the lateral
ventricles, the brain diameter, and bicaudate
ratio between the two MS groups. The cutoff
score of the V3 width predictive of cognitive
impairment was over 4.13 mm with a sensitivity
(95% CI) of 67.9% (55.6; 80.1) and a specificity
(95% CI) of 68.8% (46; 91.5). The positive
predictive value (PPV) was 88.4%.
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Table 1 Demographic characteristics of patients with MS and controls
Characteristics Patients with MS (n5 75) Controls (n5 20) P value
Age (years), mean ± SD 36.1 ± 9.2 36.9 ± 5.8 0.9
Female, n (%) 57 (76) 11 (55) 0.06
Right-handed patients, n (%) 60 (80) 17 (85) 0.61
Level of education (years), mean ± SD 12.8 ± 2.4 13.5 ± 4 0.47
MS multiple sclerosis, SD standard deviation
Table 2 Demographic characteristics of patients with multiple sclerosis with low PASAT performance compared to normal
performers
Characteristic PASAT performance P value
Impaired Unimpaired
Sample, n (%) 16 (21) 59 (79)
Age (years) 37.25 ± 9.45 36.21 ± 9.1 0.62
Disease duration (years) 8.6 ± 7.6 6.66 ± 7.24 0.35
Level of education (years) 12.44 ± 2.87 12.81 ± 2.22 0.59
Treatment duration (years) 2 ± 2 2.36 ± 3 0.67
History of immunosuppressive therapy, % 17 20 0.8
Annualized relapses rate 0.8 ± 0.56 1 ± 0.93 0.44
EDSS, median (range) 2.0 (1–5.5) 1.5 (0–5) 0.019
MSSS 3.45 ± 1.9 2.75 ± 2.2 0.22
MSFC
9HPT (s) 22.43 ± 5.06 20.05 ± 5.06 0.102
T25FW (s) 5.31 ± 1.64 4.94 ± 1.41 0.38
Normalized PASAT (/60) 22.17 – 6.27 47.48 – 7.92 <0.0001
EMIF-SEP (/100) 37.2 ± 22.4 28.8 ± 21.3 0.23
Cognitive domain (/100) 38.9 ± 22.1 27.5 ± 23.5 0.15
Physical domain (/100) 45.16 ± 26.1 37.03 ± 25.5 0.35
Psychosocial domain (/100) 37.2 ± 22.4 24.7 ± 19.8 0.06
Values are presented as mean ± standard deviation unless otherwise indicated. Bold indicates a statistically signiﬁcant
difference (P\0.05)
9HPT 9 Hole peg test, EDSS Expanded Disability Status Scale, EMIF-SEP Echelle de Mesure de l’Impact de la Fatigue sur
la SEP, MSFC Multiple Sclerosis Functional Composite, MSSS Multiple Sclerosis Severity Scale, PASAT Paced Auditory
Serial Addition Test, T25FW Timed 25-foot walk
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Correlation Analysis
A correlation analysis between the PASAT score
and the available clinical and imaging data was
performed. Significant correlation between the
PASAT and V3 width (r = -0.271, P = 0.021),
EDSS (r = -0.260, P = 0.028), and 9 Hole Peg
Test score (r = -0.294, P = 0.012) was
demonstrated.
The HV3 Score (Global Handicap
Measured by the V3)
The data were used to define a composite
clinical and radiological score easily done in
consultation. We statistically analyzed several
combinations and selected the one with better
correlation with the PASAT score. By adding the
EDSS and the V3 width, we obtained significant
correlation with the PASAT (r = -0.325,
P = 0.006; Fig. 1). This combination of EDSS
and V3 width (in mm) was called HV3 (global
handicap measured by the V3). The HV3 score
correlated better with PASAT than the EDSS or
V3 width separately (r = -0.325, P = 0.006
against r = -0.271 for V3 width and r = -
0.260 for EDSS).
At Youden plot (HV3[5.5), HV3 showed the
best properties to detect low PASAT
performance (sensitivity 66.1%, specificity
81.3%, PPV 92.5%, negative predictive value
40.6%, accuracy 70.1%; Fig. 2).
The MS group with low PASAT performance
had a significantly higher mean HV3 score
(6.81 ± 2.34) than the group without
impairment (5.3 ± 2.36; P = 0.027). Conversely,
for 81% of patients with MS with cognitive
impairment, the HV3 score was over 5.5.
Table 3 Indirect measurement of global atrophy: comparison between the MS group and control group
Measurement MS group (n5 75) Control group (n5 20) P value
V3 width (mm) 4 – 1.7 2.65 – 1.1 0.0001
Bicaudate ratio 0.115 ± 0.026 0.124 ± 0.02 0.136
Lateral ventricles width (mm) 19.22 ± 2.95 19.32 ± 2.3 0.9
Brain diameter (mm) 119.9 – 5.1 125 – 6.3 0.0003
Values are presented as mean ± standard deviation. Bold indicates a statistically signiﬁcant difference (P\0.05)
MS multiple sclerosis, V3 third ventricle
Table 4 Indirect measurement of global atrophy: comparison between the cognitively impaired patients with MS and the
unimpaired patients with MS
Measurement PASAT performance P value
Impaired (n5 16) Unimpaired (n5 59)
V3 width (mm) 4.73 – 1.49 3.72 – 1.74 0.044
Bicaudate ratio 0.122 ± 0.034 0.113 ± 0.023 0.37
Lateral ventricles width (mm) 19.18 ± 3.61 19.18 ± 2.73 1
Brain diameter (mm) 119.98 ± 6.07 119.66 ± 5.34 0.84
Values are presented as mean ± standard deviation. Bold indicates a statistically signiﬁcant difference (P\0.05)
MS multiple sclerosis, PASAT Paced Auditory Serial Addition Test, V3 third ventricle
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Local Atrophy
Compared with patients with MS without
cognitive impairment, right-handed patients
with low PASAT performance had a more
pronounced atrophy of specific brain
structures: left supplementary motor area
(SMA; P = 0.03), inferior parietal lobules
(P\0.036), cingulate gyri (P\0.039), and
right thalamus (P = 0.027).
A correlation was found between the PASAT
score and the local volume change of the left
SMA (r = 0.295, P = 0.027), the right parietal
lobe (r = 0.277, P = 0.039), left and right lower
Fig. 1 The HV3 score. HV3 is obtained by summing the V3 width (in mm; technique of determining V3 width detailed by
Benedict et al. [7]) with the EDSS. EDSS Expanded Disability Status Scale, V3 third ventricle
Fig. 2 Cutoff HV3 score predictive of low PASAT
performance. A ROC curve was used to determine the
cutoff HV3 score predicting a cognitive impairment. A
score of over 5.5 was associated with low PASAT
performance with a sensitivity (95% CI) of 66.1% (53.7;
78.5) and a speciﬁcity (95% CI) of 81.3% (62.1; 100).
PASAT Paced Auditory Serial Addition Test, ROC receiver
operating characteristic
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parietal lobules (r = 0.291, P = 0.03 and
r = 0.332, P = 0.012, respectively).
DISCUSSION
Many clinical and MRI data are associated with
cognition assessment. Although the concept of
cognitive impairment is defined as an alteration
in at least two cognitive domains, we have
chosen, in our study, to use the PASAT as a
screening test for cognitive impairment. This
test is generally considered a sensitive measure
of cognitive dysfunction patients with MS who
have mild disability [1]. It has demonstrated its
ability to evaluate several cognitive domains
simultaneously and is widely used because of its
incorporation in the MSFC score.
As with previous studies, our study
demonstrated that the V3 width was of
interest as both a marker of global atrophy
and cognitive decline [7, 25]. Cognitive
impairment in patients with MS may be
related, at least in part, to thalamic atrophy
[26]. The existence of connections between the
thalamus and many brain structures involved in
limbic functions and, in particular, the
neocortex supports this hypothesis.
Enlargement of V3 is explained by the fact
that the thalami are part of the lateral wall of
this structure. Our study objectified atrophy of
the right thalamus in patients with MS who had
a low PASAT performance. The thalamus is
involved in the working memory network and
is activated in functional MRI (fMRI) during the
PASAT [12, 20]. Moreover, Houtchens et al. [26]
showed that the EDSS was the clinical scale that
correlated with thalamic atrophy. These data
demonstrate that the width of the V3 was
closely linked to cognitive impairment as well
as disability. We also demonstrated that the left
SMA, lower parietal lobules, and the cingulate
gyri were more atrophied in the population
with a pathological PASAT score (P\0.05).
These structures have been described to be
activated in fMRI when performing the PASAT.
Frontal lobe atrophy has been demonstrated
several times in MS and is associated with
cognitive impairment [11, 27, 28]. For other
structures (lower parietal lobules and cingulate
gyri) our study is the only one, to our
knowledge, which demonstrated a link
between atrophy of these structures and
cognitive impairment. Audoin et al. [29]
showed early atrophy of the cingulate gyri in
clinically isolated syndrome but their study did
not take into account cognitive impairment.
Unlike other authors [10, 30], we did not find
any significant volume variation in the
callosum or in temporal lobes between
patients with MS with and without cognitive
impairment.
In the clinical practice, the width of the V3 is
a structure that is workable and easily
measurable by a physician using an axial
FLAIR or 3D T1w sequence on brain MRI. The
purpose of HV3 score is not to replace the
cognitive assessment but to better identify
patients requiring a full cognitive assessment.
It overcomes bias linked to the evaluator, the
test execution conditions, the patient’s fatigue,
or the retest effect, and can be done at each
visit. However, with a sensitivity score of 66.1%
(negative predictive value 40.6%), while HV3
proves effective in diagnosing cognitive
impairment in most patients, it is not enough
to suspect all of them. Moreover, this score was
defined for patients with an EDSS less than 5.5.
It therefore remains to be seen whether it can be
useful for patients with a more severe disability.
It should be interesting to design the same
study using the Symbol Digit Modalities Test or
its computerized version [31–33].
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CONCLUSION
We have established a HV3 composite score
from the EDSS and the V3 width measured by
MRI. From the beginning of the disease, even in
patients with low T2 lesion load, deep grey
matter atrophy can be detected indicating that a
degenerative process is already underway.
Knowing that thalamic atrophy correlates with
disease progression, the use of this easy and
reliable tool can be helpful for detecting
progression in patients with MS, treated or
not, even if they seems to be clinically
asymptomatic. In these patients, the challenge
is to precociously begin therapy to reduce
clinical worsening. This score is an additional
and complementary tool to suspect easily
cognitive impairment in MS. It cannot replace
a full cognitive assessment but can help to
better identify patients with MS who have a risk
of cognitive impairment.
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